CA Patent

CA3160827C — Methods of reducing the risk of cardiovascular events in a subject

Assigned to Amarin Pharmaceuticals Ireland Ltd · Expires 2025-12-23 · 0y expired

What this patent protects

This disclosure pertains to use of eicosapentaenoic acid or derivative thereof in preparation of a medicament for use in combination with a high intensity statin regimen to reduce risk of one or more of: myocardial infarction, stroke, cardiovascular death, unstable angina, corona…

USPTO Abstract

This disclosure pertains to use of eicosapentaenoic acid or derivative thereof in preparation of a medicament for use in combination with a high intensity statin regimen to reduce risk of one or more of: myocardial infarction, stroke, cardiovascular death, unstable angina, coronary revascularization procedures and hospitalizations for unstable angina in a subject, wherein the high intensity statin regimen comprises about 40 mg to about 80 mg per day of atorvastatin or about 20 mg to about 40 mg per day of rosuvastatin, and wherein the subject has elevated triglyceride levels and (1) established cardiovascular disease, or (2) diabetes and at least 2 additional risk factors for cardiovascular disease.

Drugs covered by this patent

Patent Metadata

Patent number
CA3160827C
Jurisdiction
CA
Classification
—
Expires
2025-12-23
Drug substance claim
No
Drug product claim
No
Assignee
Amarin Pharmaceuticals Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.